Harbor Capital Advisors
ABUS icon

Harbor Capital Advisors’s Arbutus Biopharma ABUS Stock Holding History

Harbor Capital Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$61K Buy
+12,805
New +$61.7K ﹤0.01% 758

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Harbor Capital Advisors's ABUS Position: Q3 2026 in Review

Harbor Capital Advisors opened a new position in Arbutus Biopharma (ABUS) in Q3 2026: 12,805 shares worth $61K. The stake represents ﹤0.01% of the portfolio and ranks #758 among its holdings.

150 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • Harbor Capital Advisors held 12,805 shares of Arbutus Biopharma worth $61K as of Q3 2026.
  • Arbutus Biopharma was a new Harbor Capital Advisors position in Q3 2026.
  • Arbutus Biopharma made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q3 2026, its #758 holding.
  • 150 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Harbor Capital Advisors's 13F filing for Q3 2026, filed 22 Oct 2026.